María José Méndez-Vidal - Researcher Profile

Publications

1 shown

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert J. Motzer , B. Yа. Alekseev , Sun Young Rha +35 more

Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme;...

2021 New England Journal of Medicine 1597 citations

Frequent Co-Authors

Researcher Info

h-index: 1
Publications: 1
Citations: 1,597
Institution: Hospital Universitario Reina Sofía

External Links

Google Scholar

Impact Metrics

h-index 1

h-index: Number of publications with at least h citations each.

Publications

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Frequent Co-Authors

Robert J. Motzer

B. Yа. Alekseev

Sun Young Rha

Camillo Porta

Masatoshi Eto

Thomas Powles

Researcher Info

External Links

Impact Metrics